Advertisement
Research Article Free access | 10.1172/JCI43522
1Department of Medicine and 2Department of Pediatrics, Naomi Berrie Diabetes Center (NBDC), Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Address correspondence to: Hong Jiang, Columbia University, College of Physicians and Surgeons, Department of Medicine, 630 W 168th Street, PH8-406, New York, New York 10032, USA. Phone: 212.305.6979; Fax: 212.305.4943; E-mail: hj4@columbia.edu.
Find articles by Jiang, H. in: JCI | PubMed | Google Scholar
1Department of Medicine and 2Department of Pediatrics, Naomi Berrie Diabetes Center (NBDC), Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Address correspondence to: Hong Jiang, Columbia University, College of Physicians and Surgeons, Department of Medicine, 630 W 168th Street, PH8-406, New York, New York 10032, USA. Phone: 212.305.6979; Fax: 212.305.4943; E-mail: hj4@columbia.edu.
Find articles by Canfield, S. in: JCI | PubMed | Google Scholar
1Department of Medicine and 2Department of Pediatrics, Naomi Berrie Diabetes Center (NBDC), Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Address correspondence to: Hong Jiang, Columbia University, College of Physicians and Surgeons, Department of Medicine, 630 W 168th Street, PH8-406, New York, New York 10032, USA. Phone: 212.305.6979; Fax: 212.305.4943; E-mail: hj4@columbia.edu.
Find articles by Gallagher, M. in: JCI | PubMed | Google Scholar
1Department of Medicine and 2Department of Pediatrics, Naomi Berrie Diabetes Center (NBDC), Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Address correspondence to: Hong Jiang, Columbia University, College of Physicians and Surgeons, Department of Medicine, 630 W 168th Street, PH8-406, New York, New York 10032, USA. Phone: 212.305.6979; Fax: 212.305.4943; E-mail: hj4@columbia.edu.
Find articles by Jiang, H. in: JCI | PubMed | Google Scholar
1Department of Medicine and 2Department of Pediatrics, Naomi Berrie Diabetes Center (NBDC), Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Address correspondence to: Hong Jiang, Columbia University, College of Physicians and Surgeons, Department of Medicine, 630 W 168th Street, PH8-406, New York, New York 10032, USA. Phone: 212.305.6979; Fax: 212.305.4943; E-mail: hj4@columbia.edu.
Find articles by Jiang, Y. in: JCI | PubMed | Google Scholar
1Department of Medicine and 2Department of Pediatrics, Naomi Berrie Diabetes Center (NBDC), Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Address correspondence to: Hong Jiang, Columbia University, College of Physicians and Surgeons, Department of Medicine, 630 W 168th Street, PH8-406, New York, New York 10032, USA. Phone: 212.305.6979; Fax: 212.305.4943; E-mail: hj4@columbia.edu.
Find articles by Zheng, Z. in: JCI | PubMed | Google Scholar
1Department of Medicine and 2Department of Pediatrics, Naomi Berrie Diabetes Center (NBDC), Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Address correspondence to: Hong Jiang, Columbia University, College of Physicians and Surgeons, Department of Medicine, 630 W 168th Street, PH8-406, New York, New York 10032, USA. Phone: 212.305.6979; Fax: 212.305.4943; E-mail: hj4@columbia.edu.
Find articles by Chess, L. in: JCI | PubMed | Google Scholar
Published September 27, 2010 - More info
Suppressing unwanted immune responses without compromising host immunity against pathogens is considered the holy grail of immunology. Lack of responsiveness to self-antigens is normally maintained by multiple mechanisms, including the suppressive activities of several T cell subsets. In this issue of the JCI, Jiang and colleagues define a CD8+ suppressor T cell subset in humans that recapitulates a regulatory pathway previously described in mice. These investigators further show that patients with type 1 diabetes have defects in their CD8+ suppressor T cells, thus identifying these cells as potential therapeutic targets in human disease.
Luc Van Kaer
A key feature of the immune system is its ability to discriminate self from nonself. Breakdown in any of the mechanisms that maintain unresponsiveness to self (a state known as self-tolerance) contributes to the development of autoimmune conditions. Recent studies in mice show that CD8+ T cells specific for the unconventional MHC class I molecule Qa-1 bound to peptides derived from the signal sequence of Hsp60 (Hsp60sp) contribute to self/nonself discrimination. However, it is unclear whether they exist in humans and play a role in human autoimmune diseases. Here we have shown that CD8+ T cells specific for Hsp60sp bound to HLA-E (the human homolog of Qa-1) exist and play an important role in maintaining peripheral self-tolerance by discriminating self from nonself in humans. Furthermore, in the majority of type 1 diabetes (T1D) patients tested, there was a specific defect in CD8+ T cell recognition of HLA-E/Hsp60sp, which was associated with failure of self/nonself discrimination. However, the defect in the CD8+ T cells from most of the T1D patients tested could be corrected in vitro by exposure to autologous immature DCs loaded with the Hsp60sp peptide. These data suggest that HLA-E–restricted CD8+ T cells may play an important role in keeping self-reactive T cells in check. Thus, correction of this defect could be a potentially effective and safe approach in the therapy of T1D.
The fundamental question of what is “self” and what is “foreign,” as seen by the immune system, determines how the immune system discriminates self from nonself. In this regard, the pioneering work of Burnet and Medawar suggested that the definition of self versus nonself is arbitrary because foreign antigens presented during fetal life are thereafter considered self (1). Moreover, it is known that all T cells are self-referential in the sense that they are positively selected for survival on self-peptide(s) bound to MHC molecules during thymic positive selection (2) before thymic negative selection, in which thymocytes expressing TCR of high avidity to self-antigens are deleted (3–5).
We have previously proposed and tested an “avidity model” of peripheral T cell regulation that postulates that, like in the thymus, the immune system discriminates self from nonself during adaptive immunity in the periphery not by recognizing the structural differences between self versus foreign antigens, but rather by perceiving the avidity of T cell activation (6–9). It is generally accepted that thymic negative selection, in which, high-avidity self-reactive thymocytes are deleted, eliminates the imminent danger of pathogenic autoimmunity in the periphery and is the major mechanism of central self-tolerance (3–5). However, while releasing the “innocent” self-reactive T cells with low avidity, thymic negative selection also allows a large fraction of self-reactive T cells of intermediate avidity to be released into the periphery under normal circumstances (10–12), and functional activation of this population of cells has the potential to elicit pathogenic autoimmunity (12–15). The potential to develop autoimmune disease is therefore inherent in every individual and must be specifically dealt with by peripheral regulatory mechanisms (6–9). In this regard, we have demonstrated in murine studies that self/nonself discrimination is accomplished by thymic negative selection followed by peripheral T cell regulation in which Qa-1–restricted CD8+ T cells selectively downregulate intermediate-avidity T cells activated by any antigens (6–8). Since the peripheral self-reactive T cell repertoire is devoid of high-avidity self-reactive cells due to thymic negative selection, the selective downregulation of intermediate-avidity T cells simultaneously enables the suppression of autoimmunity and the preservation of the functional anti-infection immunity, which is dominated by high-avidity T cells.
The concept that perceiving the avidity of T cell activation can be translated into peripheral T cell regulation is the essence of the avidity model. The cellular mechanism that defines how perceiving the avidity of T cell activation is translated into peripheral T cell regulation and the molecular structures recognized by regulatory T cells that enable them to discriminate self from nonself in the periphery are the key issues in regulatory T cell biology. In this regard, we have recently demonstrated that the heat shock peptide Hsp60sp, coupled with the MHC class Ib molecule Qa-1, is a common surrogate target structure preferentially expressed on the intermediate-avidity T cells and is specifically recognized by a subset of Qa-1–restricted CD8+ T cells (7). Thus, by a unified and simple cognitive mechanism — specific recognition of a common target structure, preferentially expressed on the intermediate-avidity T cells — the Qa-1–restricted CD8+ T cells are able to selectively target and downregulate intermediate- but not high-avidity T cells to accomplish self/nonself discrimination in the periphery (8).
The translation of the murine Qa-1–restricted CD8+ T cell–mediated pathway to humans is based on evidence that the human homolog of Qa-1, HLA-E, can function as a restricting element for human regulatory CD8+ T cells (16). Here we show that humans have a cognitive mechanism similar to that discovered in mice, in which HLA-E–restricted CD8+ T cells, the human counterpart of murine Qa-1–restricted CD8+ T cells, function to maintain self-tolerance in healthy humans by discriminating self from nonself in the periphery. In addition, we provide evidence that the HLA-E–restricted regulatory CD8+ T cell–mediated pathway plays a role in the immunopathogenesis of the human autoimmune disease type 1 diabetes (T1D). T1D is an autoimmune disorder in which T cells reactive with major antigenic components of pancreatic β cells have a central role. While these self-reactive T cells are under the control of peripheral regulatory mechanisms in healthy individuals, failure of the control leads to the destruction of the β cells and consequent T1D (17, 18). To directly test this idea, we studied patients with T1D and found that, in the majority of the patients tested, HLA-E–restricted CD8+ T cells have a cognitive defect in their capacity to recognize the specific common target structure, HLA-E/Hsp60sp, expressed on target cells, and functionally fail to mediate self/nonself discrimination. Moreover, this cognitive and functional defect in the CD8+ T cells in most patients can be corrected by an in vitro boost of CD8+ T cells with autologous immature DCs loaded with Hsp60sp peptide. Taken together, these studies provide evidence that the CD8+ T cell recognition of HLA-E/Hsp60sp may be a central cognitive mechanism enabling self/nonself discrimination in the periphery and that the defect of this pathway may be involved in the development and control of T1D.
Generation of human HLA-E–restricted CD8+ T cell lines that specifically recognize HLA-E/Hsp60sp expressed on the target cells
We have shown previously that murine immature DCs loaded with the Qa-1–binding peptide Hsp60sp, but not Qdm, can be used as a vaccine to induce CD8+ T cell–dependent protection from EAE (7). This observation suggested that functional HLA-E/Qa-1–restricted CD8+ T cells could be induced by Hsp60sp-loaded immature DCs in vivo. It is well known that Qdm is the leader sequence derived from conventional MHC class Ia proteins in mice that is capable of binding to Qa-1 (19). Importantly, the resultant Qa-1/Qdm complex is the specific ligand for NKG2A receptor on NK cells, and the recognition of this ligand by NK cells can inhibit NK killing (20–22). Thus, B7sp, the human equivalent of Qdm (23), was used as an ideal control HLA-E–binding peptide for Hsp60sp in our current human studies. Employing this approach, we established a standard protocol and successfully generated two types of human CD8+ T cell lines in vitro from healthy individuals by stimulating purified peripheral CD8+ T cells with autologous immature DCs loaded either with Hsp60sp, designated CD8(H) cells, or loaded with HLA-B7sp, designated CD8(B) cells.
The CD8+ T cell lines generated from the healthy donors were first tested to determine whether they recognize HLA-E/Hsp60sp expressed on the target T cells. We thus established human transfectant cell lines that express HLA-E on their surface to identify the HLA-E–binding peptide(s) that could be recognized by the regulatory CD8+ T cells. An HLA-E expression construct was established and transfected into a human HLA-A/B/C–deficient B cell line, B721 (24). HLA-E expression clones were generated by limiting dilution. The cloned B721/HLA-E transfectants (B721/E) were first tested for their surface expression of HLA-E by staining the peptide-loaded B721/E cells with HLA-E–specific mAb 3D-12 (25). Consistent with other reports (7, 23), both B7sp and Hsp60sp bound to HLA-E and, therefore, stabilized the expression of HLA-E on the cell surface (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI43522DS1), and thus could be used as HLA-E–binding peptide–presenting cells to test the specific recognition of the target structure by the HLA-E–restricted CD8+ T cells in a CD8+ T cell inhibition assay (7, 8).
Hsp60sp-specific CD8+ T cells inhibit HLA-E–expressing cells loaded with Hsp60sp but not control peptide B7sp
We then investigated the specificity of the CD8(H) lines generated from the healthy individuals by testing the inhibitory effect of the CD8(H) lines on the HLA-E–expressing transfectant B721/E cells loaded with Hsp60sp, B7sp, or control non–HLA-E–binding peptide (CD8+ T cell inhibition assay). The CD8(H) lines consistently showed in all individuals tested a potent suppression of B721/E cells loaded with Hsp60sp but not B721/E cells loaded with B7sp or control peptide (see representative results in Figure 1A). Moreover, the control CD8(B) lines did not suppress the B721/E targets loaded with any peptides. The specific cognitive recognition of HLA-E/Hsp60sp expressed on the target cells by the HLA-E–restricted CD8+ T cells was further confirmed by the detection of cytolytic enzymes (CEs) secreted by the HLA-E–restricted CD8+ T cells. Thus, increased secretion of CEs, such as perforin, granzyme A, and granzyme B, by the CD8+ T cells was observed when the CD8(H) lines were cocultured with B721/E cells loaded with Hsp60sp but not with B721/E cells loaded with control peptide B7sp, or when CD8(B) lines were cocultured with B721/E cells loaded with Hsp60sp or B7sp, as shown by representative results in Figure 1B. These observations were precisely correlated with the specific killing of targets by the CD8(H) lines that were loaded with Hsp60sp but not B7sp, as detected in the CD8+ T cell inhibition assay above.
Generation of human HLA-E–restricted CD8+ T cell lines that function to discriminate self from nonself by specifically recognizing HLA-E/Hsp60sp expressed on the target cells. (A) CD8(H) lines from healthy individuals specifically inhibit HLA-E–expressing cells loaded with Hsp60sp. CD8(H) and control lines were generated and tested in a CD8+ T cell inhibition assay as described in Methods. Data represent mean ± SEM and were from 3 healthy normal individuals. Ctr pep, control peptide. (B) Increased CE expression by the HLA-E–restricted CD8+ T cells triggered by the specific target structure HLA-E/Hsp60sp. CD8(H) and CD(B) lines from healthy individuals were cocultured with B721/E cells loaded with peptide Hsp60sp or control peptide B7sp. The CE expression by the CD8+ T cells was detected by 3-color intracellular staining with perforin (Perf), granzyme A (GA), and granzyme B (GB), followed by FACS analysis as described in Methods. Shown are representative data from 1 of 3 healthy normal individuals. Top row: CE expression indexes of 3 different combinations of CE expression; bottom row: intracellular staining patterns of the CEs on the CD8(H) lines. (C) CD8(H) lines from healthy individuals suppress the overall immune responses to self-antigens MBP and GAD but enhance the immune responses to foreign antigens TT and PPD. CD8(H) and control CD8(B) lines were generated and tested in a self/nonself discrimination assay as described in Methods. Data are shown as mean ± SEM and were from 3 healthy normal individuals. 3Hdtr, [3H]thymidine. YRK, YL, and AJ designate individual normal healthy controls.
We concluded from these experiments that the ability of CD8(H) but not CD8(B) cells to specifically recognize Hsp60sp presented by HLA-E strongly suggested that the CD8(H) and CD(B) cells may represent functionally distinct subsets of CD8+ T cells with respect to specificity and function.
HLA-E–restricted CD8+ T cells function to discriminate self from nonself in the periphery
We next directly tested the function of self/nonself discrimination by systematically testing the effect of the CD8(H) lines on the overall avidity of immune responses to self-antigens myelin basic protein (MBP) (or glutamic acid decarboxylase [GAD]) versus those to foreign antigens tetanus toxoid (TT) (or purified protein derivative [PPD]) in a standard T cell proliferation assay as described previously (8). Thus, purified autologous CD4+ T cells were activated by serial doses of either MBP (and GAD) or TT (and PPD), and CD8(H) cells were added to the CD4+ T cell cultures. CD8(B) and CD8(N) (primed with DCs without being loaded with peptides) served as controls. In the studies using GAD as a self-antigen, the donors were selected to be DR4+. As shown in Figure 1C, in the same individuals shown in Figure 1A, the CD8(H) cells suppressed the responses to self-antigens MBP and GAD but enhanced the responses to foreign antigens TT and PPD, compared with control CD8(B) or CD8(N) cells (see data from all controls and T1D patients presented below). The typical pattern of an inhibited immune response was shown by a decreased overall avidity, reflected by an increased median effective dose (ED50), in immune responses to self-antigen MBP and GAD in the presence of CD8(H) compared with the responses to the same antigens in the presence of control CD8(B) and CD8(N) cells. In contrast, the typical pattern of an enhanced immune response was shown by an increased overall avidity, reflected by a decreased ED50, in immune responses to foreign antigen TT and PPD in the presence of CD8(H) compared with the responses to the same antigens in the presence of control CD8(B) and CD8(N) cells.
Taken together, the results suggest that combination of the two functional assays provides a unique and reliable assay system that enables the precise identification and detection of human HLA-E–restricted CD8+ T cell populations. Moreover, it links the specificity of HLA-E–restricted CD8+ T cells to their biological function of self/nonself discrimination. These cognitive and functional properties together make a clear distinction between the unique CD8+ T cells that recognize Hsp60sp bound by HLA-E [CD8(H)] and the CD8+ T cells recognizing HLA-E binding to other peptides, such as the HLA-E/B7sp complex [CD8(B)]. This observation indicates that a major consequence of regulation by the HLA-E–restricted, Hsp60sp-specific CD8+ T cells is its differential effect on the overall immune response to self versus to foreign antigens. These studies demonstrate that HLA-E–restricted, Hsp60sp-specific CD8+ T cells, which are capable of discriminating self from nonself, exist and function in healthy human subjects.
Do HLA-E–restricted CD8+ T cells that function to discriminate self from nonself play a role in the development and control of human T1D?
To determine whether HLA-E–restricted CD8+ T cells also play a role in the control of human T1D, we tested the function of CD8+ T cells from patients at the NBDC with recent-onset T1Ds. We demonstrate below that via the same mechanism identified in mice, HLA-E–restricted CD8+ T cells exist and play an important role in maintaining self-tolerance in healthy humans by discriminating self from nonself in the periphery and that this functional property was defective in a majority of the T1D patients tested.
A defect in the HLA-E–restricted CD8+ T cell–mediated pathway is detected in a majority of the T1D patients tested
We previously demonstrated that Qa-1–restricted CD8+ T cells control the spontaneous development of T1D in NOD mice, in part, by means of self/nonself discrimination (8). To determine whether HLA-E–restricted CD8+ T cells also play a role in the control of human T1D, we tested the function of freshly isolated CD8+ T cells from 10 patients with recent onset of T1D. The standard antigens chosen were TT for foreign antigen and GAD and MBP for self-antigens, and each patient tested was selected as DR4+ and paired with a DR4+ healthy normal control.
CD8+ T cells freshly isolated from most of the T1D patients tested fail to recognize specific target structure HLA-E/Hsp60sp expressed on target cells. We first identified the specificity of the CD8+ T cells as described above. Representative results presented in Figure 2A show that while CD8+ T cells from a normal control specifically inhibited the B721/E cells loaded with Hsp60sp, but not control peptides, CD8+ T cells from a T1D patient failed to inhibit B721/E cells loaded with Hsp60sp. Moreover, as summarized in Table 1, freshly isolated CD8+ T cells from 9 of 10 T1D patients tested failed to specifically inhibit B721/E cells loaded with Hsp60sp, compared with normal controls (P < 0.001), precisely correlating with the failure of self/nonself discrimination in each patient as summarized in Figure 2C (see below).
A defect in the HLA-E–restricted CD8+ T cell–mediated pathway is detected in a majority of the T1D patients tested. (A) Freshly isolated CD8+ T cells from a T1D patient lost the capacity to specifically recognize HLA-E/Hsp60sp target structure. CD8+ T cells were purified from T1D patients and tested in a CD8+ T cell inhibition assay as described in Methods. Data show mean ± SEM and are representative of 9 of 10 T1D patients tested (P) paired with healthy normal controls (C). (B) Freshly isolated CD8+ T cells from a T1D patient lost the capacity to discriminate self from nonself. CD8+ and CD4+ T cells were purified from T1D patients, and responses of CD4+ T cells were tested and compared in the presence and absence of CD8+ T cells in a standard self/nonself discrimination assay as described in Methods. Data are shown as mean ± SEM and are representative of 9 of 10 T1D patients tested paired with healthy normal controls. (C) Freshly isolated CD8+ T cells from the majority of the T1D patients tested lost the capacity to discriminate self from nonself in the periphery. Immune responses of purified CD4+ T cells to self-antigen GAD versus to foreign antigen TT were compared with those of CD4+ T cells plus CD8+ T cells in each T1D patient, paired with normal control. Data summarize 10 T1D patients and corresponding controls and are representative of 2 tests for each patient.
Comparison of the specificity of freshly isolated CD8+ T cells between T1D patients and normal controls
CD8+ T cells freshly isolated from most of the T1D patients tested have a defect in the capacity to discriminate self from nonself. We then compared the overall immune responses of purified CD4+ T cells to self versus foreign antigens in the presence or absence of freshly isolated CD8+ T cells. Representative results in 9 of 10 T1D patients tested compared with normal controls are shown in Figure 2B. Thus, the CD8+ T cells from normal controls significantly depressed the overall CD4+ T cell response to self-antigen GAD, reflected by an increased ED50, while enhancing the overall response to foreign antigen TT, reflected by a decreased ED50, compared with CD4+ T cell cultures without CD8+ T cells. However, when the same tests were performed in the T1D patients, there was no significant difference in ED50 between purified CD4+ T cells with and those without CD8+ T cells responding to either self-antigen GAD or to foreign antigen TT, indicating that CD8+ T cells from T1D patients have a defect in or have lost the capacity to discriminate self from nonself.
In addition to ED50, a new parameter was designed to evaluate the data from the self/nonself discrimination assay: the self/nonself discrimination index (SND index). The SND index represents the antigen dose that elicits the highest T cell proliferation of immune response to a particular antigen and can be used to directly reveal the relationship of T cell responsiveness to self versus to foreign antigens in each individual. This can be graphically shown by a line connecting SND index of TT versus GAD or MBP in each test. The direction of the connecting line in each individual indicates the relationship between immune responses elicited by self versus by foreign antigens. A high SND reflects a reduced antigen-specific responsiveness, and conversely, falling SND indicates increasing antigen responsiveness. When data from more than 200 tests performed in both normal controls and T1D patients were analyzed side-by-side using SND index and ED50 as parameters to evaluate the responsiveness of T cells, SND indexes were always consistent with ED50 in each test. Thus, SND index was used as an additional simple and straightforward parameter to present the summarized data from self/nonself discrimination assay throughout this study.
Results from 10 T1D patients with corresponding controls are summarized in Figure 2C and Supplemental Table 1. Notably, in the absence of CD8+ T cells, the responses to self-antigen GAD were higher than to foreign antigen TT, reflected by lower SND indexes for GAD than for TT, in both T1D and normal controls. In the presence of CD8+ T cells, the normal controls exhibited the reverse phenomenon: the GAD responses were inhibited (reflected by increased SND indexes) among all individuals tested, while responsiveness to foreign antigen (TT) was increased. In contrast, 9 of 10 T1D patients tested showed the same distribution pattern of SND indexes, regardless of the presence or absence of CD8+ T cells, suggesting that the presence of CD8+ T cells in the culture had no significant impact on antigen-driven proliferation in those T1D patients. This observation was further confirmed in cultures examining reactivity to another (T1D-unrelated) self-antigen, MBP (Supplemental Figure 2 and Supplemental Table 2).
The CD8+ T cells from most T1D patients tested could be boosted in vitro to restore their function
We further tested whether the specific cognitive defect of CD8+ T cells from T1D patients could be corrected by boosting the CD8+ T cells. Thus, the CD8+ T cells from the T1D patients were boosted in vitro by priming with autologous immature DCs loaded with Hsp60sp [CD8(H)] or B7sp [CD8(B)] or not loaded with peptide [CD8(N)], as described above.
The function of the boosted CD8+ T lines was first tested for their specificity in a CD8+ T cell inhibition assay. As shown in Figure 3A, CD8(H) cells from a T1D patient specifically inhibited B721/E cells loaded with Hsp60sp, but not B7sp or control peptide, as effectively as those form a healthy individual. CD8(B) cells from the same patient did not inhibit at all. As summarized in Table 2, this phenomenon was also observed in 8 of 9 T1D patients originally found to have a defect in their CD8+ T cells. However, the function of the CD8+ T cells in 1 of 9 T1D patients (no. 7) was not restored by just a simple boost in vitro. After restoration of the function of the CD8+ T cells in the 8 subjects who responded, statistical analysis showed no significant difference between the CD8+ T cells of the T1D group and a normal control group with regard to their ability to specifically inhibit HLA-E–expressing targets loaded with Hsp60sp (P = 0.98 without T1D subject no. 7).
The CD8+ T cells from most T1D patients tested could be boosted in vitro to restore their function. (A) CD8+ T cells from a T1D patient restored the capacity to specifically recognize the target structure HLA-E/Hsp60sp, after being boosted in vitro with autologous DCs loaded with Hsp60sp peptide. CD8(H) and control CD8+ lines were generated from each T1D patient and corresponding normal control and were tested and compared in a CD8+ T cell inhibition assay. Data are shown as mean ± SEM and are representative of 8 of 9 T1D patients who originally tested with a defect of the HLA-E–restricted CD8+ T cells. (B) CD8+ T cells from a T1D patient restored the capacity to discriminate self from nonself after an in vitro boost with autologous DCs loaded with Hsp60sp peptide. CD8(H) and control CD8(B) lines were generated from each T1D patient and corresponding normal control and tested and compared in a self/nonself discrimination assay. Data are shown as mean ± SEM and are representative of 8 of 9 T1D patients who originally tested with defect of the HLA-E–restricted CD8+ T cells. (C) CD8+ T cells from most T1D patients tested regain the capacity to discriminate self from nonself after an in vitro boost. Immune responses of in vitro established CD8(H) lines to self-antigen GAD versus to foreign antigen TT were compared with those of CD8(B) and CD8(N) lines in each T1D patient, paired with normal control. Data summarize 10 T1D patients and correspondent controls and are representative of 2 tests for each patient.
Representative results on restored function of self/nonself discrimination are shown in Figure 3B. CD8(H) lines, generated from the same 8 of 9 T1D patients by an in vitro boost with the autologous DCs loaded with Hsp60sp, regained the function of self/nonself discrimination compared with the normal controls. As summarized in Figure 3C and Supplemental Table 3, in the presence of the control CD8(N) and CD8(B) lines, the SND indexes were significantly lower in CD4+ T cells responding to GAD than to TT (P < 0.05) in both T1D and normal control groups, reflecting an uncontrolled reactivity to self-antigen GAD. However, when CD8(H) cells were added into the CD4+ T cell cultures, in 9 of 10 patients (except patient no. 7) and 10 normal controls, the SND indexes became significantly higher in GAD responses than in TT responses (P < 0.05). Thus, under the control of the CD8(H) lines, an inhibited immune response to self-antigen GAD associated with an increased immune response to foreign antigen TT was detected in most of the T1D patients compared with the normal controls.
Thus, CD8+ T cells from most T1D patients tested could regain their specific cognitive function, at a molecular/cellular level, by an in vitro boost with autologous immature DCs loaded with Hsp60sp, leading to a restoration of their ability to discriminate self from nonself at a biological system level.
Our current studies provide evidence that via the same cognitive mechanism that we have identified in mice, the HLA-E–restricted CD8+ T cells that function to discriminate self from nonself do exist and operate in humans. Furthermore, we found that the HLA-E–restricted CD8+ T cells have a specific cognitive defect in a large fraction of T1D patients, suggesting that this defect may be involved in the development and control of T1D.
The specificity of HLA-E–restricted CD8+ T cells determines their biological function of self/nonself discrimination: the molecular/cellular mechanism of self/nonself discrimination. In a 1990 editorial in Science, Daniel E. Koshland Jr. wrote, “Of all the mysteries of modern science, the mechanism of self versus nonself recognition in the immune system ranks at or near the top” (26). Clearly, self-tolerance must be achieved by mechanisms of self/nonself discrimination. However, in the field of immune regulation, this concept seems to be ignored when the peripheral mechanisms of self-tolerance are studied. Despite the numerous research articles written during the last several decades on the peripheral regulation of the immune responses in both human autoimmune disease and murine models of autoimmunity, few, if any, directly dealt with the cognitive mechanisms of peripheral self/nonself discrimination (9). In this regard, discrimination of self from nonself and control of the magnitude and class of the immune response are two equally important but distinct peripheral regulatory mechanisms that operate in concert to ensure optimal function of the immune system (9, 27, 28). In general, while mechanisms of self/nonself discrimination evolve to establish and maintain self-tolerance, control of the magnitude and class of the immune response serves to ensure an optimal response to foreign pathogens by avoiding collateral damage from excessive reactions or an improper response due to an inadequate class of immune response (9, 27, 28). However, currently, almost all the identified peripheral regulatory mechanisms including those employed by the various types of regulatory CD4+ T cells function by controlling the magnitude and class of immune responses (27, 28). While this is important, it does not provide a biological basis for the specificity required to precisely, safely, and effectively prevent and treat human organ-specific autoimmune diseases caused by failure of peripheral self/nonself discrimination (9, 16, 28, 29). In this regard, we have demonstrated in mice that one of the central characteristics of the HLA-E/Qa-1–restricted CD8+ T cell–mediated pathway is its unique specificity of regulation. The specificity of the regulation is not at the level of antigens that activate the target T cells but at the level of the particular common surrogate target structure, such as Qa-1/Hsp60sp, preferentially expressed on the target T cells as a function of intermediate-avidity activation (6, 7), which could be initiated by any antigens (8). This feature of the HLA-E/Qa-1–restricted CD8+ T cells enables the immune system to employ a unified and simple cognitive molecular/cellular mechanism, at a biological system level, to discriminate self from nonself, in order to maintain self-tolerance. The observation in our current studies that defects in this cognitive recognition of HLA-E/Hsp60sp by the HLA-E–restricted CD8+ T cells were associated with failure of self/nonself discrimination in the majority T1D patients tested provides evidence from human disease that supports this notion. This is also supported by independent studies in Qa-1–KO mice (30) and, more precisely, in Qa-1 mutant knock-in mice possessing impaired Qa-1 binding to the TCR/CD8 coreceptor (31), providing direct and unequivocal molecular evidence that the cognitive recognition of Qa-1/peptide on the target T cells by the Qa-1–restricted CD8+ T cells is crucial in maintaining self-tolerance.
The significance of HLA-E–restricted CD8+ T cells in maintaining peripheral self-tolerance has been demonstrated by self/nonself discrimination assays in our current studies. In all the tests performed with different settings in normal controls, the immune responses of CD4+ T cells to self-antigens were always significantly higher than (P < 0.05) or the same as immune responses to foreign antigens, reflected by the lower or similar SND indexes, in the absence of the HLA-E–restricted CD8+ T cells. In contrast, in all the tests containing the HLA-E–restricted CD8+ T cells, the immune responses of CD4+ T cells to self-antigens were always significantly lower (P < 0.05), reflected by the higher SND indexes, compared with immune responses to foreign antigens, without any exceptions (Supplemental Tables 1–3, Figure 2C, Figure 3C, and Supplemental Figure 2). This notion is further supported by the fact that the majority of the T1D patients tested have lost the function of their HLA-E–restricted CD8+ T cells.
Given the observations in mice that intermediate-avidity T cells preferentially express a common target structure on their surface (7–9), we have established two assays based on the central biology of this regulatory pathway. These two assays, together, transformed the basic science into a direct and practical approach in humans to identify HLA-E–restricted CD8+ T cells. Thus, detection of the specificity of the HLA-E–restricted CD8+ T cells recognizing HLAE/Hsp60sp preferentially expressed on intermediate-avidity target T cells can be directly linked to the biological function of self/nonself discrimination at a system level without the need for indirectly identifying the intermediate-avidity target T cells at a clonal level. As importantly, self/nonself discrimination can be experimentally detected only at a system level but not at a clonal level, to reveal its biological and functional significance. Taken together, the results suggest that definitive specificity of the HLA-E–restricted CD8+ T cells in combination with their biological function of self/nonself discrimination have led to the conclusion that the molecular/cellular mechanism of self/nonself discrimination in our system is mediated by the HLA-E–restricted CD8+ T cells that selectively downregulate the target T cells expressing HLA-E/Hsp60sp.
These two assays together provide a unique and reliable assay system enabling the identification of the specificity (7) and the determination of the biological function of self/nonself discrimination (8) of human HLA-E–restricted CD8+ T cells in both basic and clinical studies. The data obtained by these assays are statistically significant (Tables 1 and 2 and Supplemental Tables 1–3) and consistent with the murine observations that the degree and magnitude of the regulation detected are sufficient to effectively protect animals from T1D and EAE (7, 8).
It is of interest that Qa-1/HLA-E is a central molecule that links the NK pathway to the T cell regulation. We demonstrated in our current studies that via a specific cognitive recognition of the HLA-E/Hsp60sp expressed on the target T cells, the HLA-E–restricted CD8+ T cells discriminate self from nonself in the periphery. It could be postulated that the target T cells expressing higher levels of HLA-E/Hsp60sp would express less HLA-E/B7sp on their surface and, therefore, be more susceptible to NK killing as well. This may link the regulation of adaptive immunity to innate immunity in the context of self/nonself discrimination, which should be further explored (9).
The in vivo relevance of the HLA-E–restricted CD8+ T cell–mediated pathway suggested by the current studies. The relevance of the assay system to in vivo activities of the HLA-E–restricted CD8+ T cell population was shown by two major sets of results. First, in samples from healthy individuals, there were no functional differences between freshly isolated CD8+ T cells (Figure 2 and Table 1) and in vitro boosted HLA-E–restricted CD8+ T cells (Figure 3 and Table 2), as revealed by the two assays. These data indicated that HLA-E–restricted CD8+ T cells are constantly activated and function in vivo in healthy people. The in vivo relevance of in vitro generation of CD8(H) and CD8(B) lines is also supported by the observation that vaccinating animals with Hsp60sp-loaded, but not Qdm-loaded, DCs can induce a CD8+ T cell–dependent protection from EAE (7). Second, Figure 2, A–C, presents the data comparing the function of freshly isolated CD8+ T cells from blood of T1D patients and normal controls, revealed by the specificity and self/nonself discrimination assays. These cells were not manipulated in vitro. The cognitive defects of the HLA-E–restricted CD8+ T cells in most of T1D patients tested, compared with normal individuals, represent the direct relevance of this regulatory pathway in vivo. In addition, since the in vivo relevance of the in vitro generated CD8+ T cell lines have been demonstrated in normal controls, these cellular reagents could be used for providing extremely useful information if the defect of the CD8+ T cells from T1D patients can be corrected by an in vitro boost with autologous DCs loaded with Hsp60sp in clinical settings for potential prognosis.
In the current studies, among the 10 T1D patients tested, 9 revealed evidence of a specific cognitive defect of HLA-E–restricted CD8+ T cells, with one exception, patient no. 4. The high incidence of the defect of the HLA-E–restricted CD8+ T cells in the T1D patients tested makes it possible to postulate that HLA-E–restricted CD8+ T cell–mediated pathway may play a major role in the development and control of human T1D. However, CD8+ T cells from patient no. 7 could not be corrected. This observation indicates that the specific cognitive defect of the CD8+ T cells in this patient may not be at the level of the CD8+ T cell itself, but at the level of either DCs, which may not be capable of inducing the CD8+ T cells, or CD4+ T cells, which may not be susceptible to the CD8+ T cell regulation. An alternative interpretation would be that a small portion of T1D patients might have a diminished ability to respond to foreign antigens associated with elevated ability to respond to self-antigen independent of HLA-E–restricted CD8+ T cells. The ability to identify the subset of T1D patients with a defect of HLA-E–restricted CD8+ T cells will enable future natural history studies in T1D to determine whether the function of these regulatory cells correlates with clinical course.
Identification of the peripheral regulatory mechanisms that function to discriminate self from nonself would enable novel clinical interventions to prevent and treat autoimmune diseases without damaging anti-infection and antitumor immunity, which is a major side effect of the immunotherapeutic trials currently under investigation for the treatment of T1D. Our findings suggest a potential treatment of T1D via vaccination of patients with autologous immature DCs loaded with Hsp60sp to specifically activate the HLA-E–restricted CD8+ T cells in vivo. This potential therapeutic approach is supported by the fact that vaccinating B10PL mice with immature DCs loaded with Hsp60sp, but not control peptide Qdm, effectively protected animals from subsequently induced EAE and that the protection was CD8+ T cell dependent (7). If proven correct in vivo in humans, this approach would specifically prevent continuous destruction of “regenerated” β cells that may arise spontaneously or by any possible advanced modern therapeutic technology, such as stem cell transplantation, in established T1D patients. Furthermore, the unique assay system may improve our ability to accurately predict the development of T1D and may allow earlier diagnosis of patients. β Cell mass decreases during the asymptomatic prodromal period of pre-T1D (32, 33), so diagnosis and intervention at the earliest stages could potentially provide an opportunity to intervene before any significant destruction of β cells occurs.
Reagents and human samples. Anti–HLA-E mAb 3D-12 and control mAb 4D-12 were a gift from Daniel Geraghty (Fred Hutchinson Cancer Research Center, Seattle, Washington, USA). The staining reagents — fluorescein-conjugated (Fl-conjugated) anti–human CD8, phycoerythrin-conjugated (PE-conjugated) anti–human CD4, Fl-conjugated goat anti-mouse, PE–anti–human perforin, Fl–anti–human granzyme A, and Cy-Streptavidin — were purchased from BD. Biotin-conjugated (Bio-conjugated) anti–human granzyme B was purchased from R&D Systems. Peptides — hHSP60sp (QMRPVSRVL); hB7sp (VMAPRTVLL); TTp830-843 (QYIKANSKFIGITE); hGAD65p555-567 (NFFRMVISNPAAT); hMBPp84-102 (NPVVHFFKNIVTPRTPPP) — were synthesized by GeneScript Corp. PPD was purchased from Sanofi Pasteur Ltd.
Blood samples from T1D patients and controls were obtained under a protocol approved by the institutional review board of Columbia University College of Physicians and Surgeons. All subjects (or their guardians) provided written informed consent.
Preparation of human PBMCs and purified CD8+ and CD4+ T cells. PBMCs were prepared from heparinized blood, which was diluted 1:1 with HBSS and layered over Ficoll-Hypaque, and centrifuged at 1,000 g for 30 minutes in a Sorvall RC-3 centrifuge (Ivan Sorvall Inc.). The lymphocytes at the serum-Ficoll interface were removed and washed 3 times in preparation for further purification of subsets. Both CD8+ and CD4+ T cells in all experiments presented in this study were positively selected by MACS magnetic beads (Miltenyi Biotec) as described previously (6). Briefly, the PBMCs were incubated with anti–human CD4- or CD8–conjugated magnetic beads at 10 × 106 cells/10 μl of beads, and the CD+ and CD– populations were isolated using a separation column exposed to a magnetic field according to the manufacturer’s protocol. The purity of the CD4+ or CD8+ T cells was greater than 95%.
Generation of HLA-E expression transfectants. HLA-E fusion construct (pDsRed) was engineered by RT-PCR from the human B cell line B721 using the following primers: CCAAGCTTATGGTAGATGGAACCCTCCTTT (forward) and GGGGATCCAACAAGCTGTGAGACTCAGACCC (reverse). Amplified clones in pCR2.1 were fully sequenced. Six independent full-length clones representing the HLA-E 101 haplotype but lacking the 3′ termination codon were subcloned into the mammalian expression vector pDsRed-Express-N1 (Clontech Laboratories Inc.), yielding a single open reading frame encoding a fusion protein consisting of HLA-E joined to a variant of the Discosoma species red fluorescent protein (Clontech Laboratories Inc.). The pDsRed–HLA-E construct was introduced into the HLA class I–deficient B cell line B721 (24) by electroporation, and stable clones were selected by subcloning in Geneticin (G418).
Testing HLA-E surface expression of HLA-E transfectants. We assessed the surface expression of HLA-E on B721 cells transfected with HLA-E by exogenously loading the cells with hHsp60sp and B7sp or control non–HLA-E–binding peptides at 26°C for 18 hours. Cells were then washed, stained with anti–HLA-E mAb 3D-12 (25) followed by Fl–goat anti-mouse Ig, and analyzed on a FACScan flow cytometer and by CellQuest software (BD) as previously described (6). mAb 4D-12 served as control (25).
Generation of HLA-E–restricted Hsp60sp-specific CD8+ T cell lines. DCs were derived from PBMCs depleted of CD4+ and CD8+ T cells and were cultured in 6-well plates in serum-free Click’s medium at 37°C, 5% CO2, for 1–1.5 hours. The wells were gently washed. The nonadherent cells were washed away, and the adherent cells were then cultured in medium containing GM-CSF and IL-4 at final concentrations of 80 ng/ml and 20 ng/ml, respectively. DCs were harvested on D6 and loaded with Hsp60sp, B7sp, or no peptide at 50 μM, 37°C, for 2 hours. The purified CD8+ T cells (1.5 × 106 to 2 × 106) were then cocultured with 0.5 × 106 peptide-loaded DCs in 1 ml in a 48-well plate to set up the lines of CD8(H), CD8(B), and CD8(N) cells. IL-2 was added on the second day. These 3 types of lines were established for each T1D patient and control through out this study.
CD8+ T cell inhibition assay. Freshly isolated CD8+ T cells were purified from PBMCs, and CD8(H) and CD8(B) lines were generated as described. HLA-E–transfected cells (B721/E) served as targets and were passively loaded with testing peptides — Hsp60sp, B7sp, and control non–HLA-E–binding peptide — overnight at 26°C. Equal numbers of unlabeled B721/E cells loaded with peptides and CFSE-labeled parental B721 cells that were not loaded with peptide were mixed, and testing CD8+ T cells were added to the targets at graded E/T ratios, from 3:1 to 0.005:1. We studied the specificity of freshly isolated CD8+ T cells by comparing their inhibition of target B721/E cells loaded with Hsp60sp versus those loaded with B7sp. In addition, the specificity of CD8(H) lines was compared with that of control CD8(B) lines. In this regard, we established that CD8(H) cells tested had no effect on B721 cells alone or B721 cells pulsed with Hsp60sp or B7sp. On day 5–6, the cell mixtures were assessed by FACS analysis, in which the CD8+ T cells were gated out during the analysis. The ratio between the two types of targets was calculated and compared in the presence or absence of the CD8+ T cells to evaluate the effect of testing CD8+ T cells on the targets. The percent specific inhibition was calculated as: {[ratio of loaded B721/E versus unloaded B721 cells in control cultures (without CD8+ T cells) – ratio in experimental cultures (with CD8+ T cells)]/ratio in control cultures} × 100 (7, 8). Statistical analysis by 2-tailed Student’s t test of the highest percentage of the inhibition was used to evaluate significant differences among different groups (P < 0.05).
Detection of intracellular CEs secreted by the CD8+ T cells. CD8(H) and CD8(B) lines were generated from healthy individuals as described. The established HLA-E–transfected cells (B721/E) served as targets to trigger the CD8+ T cells and were passively loaded with Hsp60sp peptide overnight at 26°C, and the B7sp peptide served as control. Testing CD8(H) and CD8(B) cells were added to the target B721/E cells loaded with different peptides at graded E/T ratios, from 3:1 to 0.005:1. At different time points, 3-color intracellular staining was performed on the cell mixture with anti-perforin–PE, anti–granzyme A–FITC, and anti–granzyme B–Bio/Cy following the manufacturer’s instructions (BD). The cells were assessed by FACS analysis, in which the CD8+ T cells were gated in during the analysis. The CE expression index was calculated as a function of different E/T ratios: ([% of double-positive CE-stained CD8+ T cells from different E/T ratio cultures] – [% of double-positive CE-stained CD8+ T cells from the CD8+ T cells that were not triggered by the target cells])/% of double-positive CE-stained CD8+ T cells from the CD8+ T cells that were not triggered by the target cells.
Self/nonself discrimination assay. All the donors were initially screened for specific and detectable CD4+ T cell responses to self-antigens MBP (hMBPp84-102) or GAD (hGAD65p555-567) versus to foreign antigens TT (TTp830-843) or PPD in a standard T cell proliferation assay as described, according to the experimental design. Purified CD4+ T cells were activated, in the presence of irradiated PBMCs as APCs, by a series of doses, ranging from 0.08 to 50 μM (PPD was titrated and used at ratios ranging from 1:12,500 to 1:20, corresponding to 0.08–50 μM) of either GAD (or MBP) or TT (or PPD) for 18–24 hours. Antigens were washed away, and the mixture of 1 × 105 purified CD4+ T cells plus 1.5 × 105 irradiated PBMCs per well were plated into round-bottom 96-well plates in AIM V serum-free lymphocyte medium (GIBCO, Invitrogen) supplemented with l-glutamine at 1 mM. CD8+ T cells were also added to the CD4+ T cells at an E/T ratio of 0.1:1 to 0.2:1 and further cultured for an additional 5–6 days. In this regard, we titrated the amount of the CD8+ T cells added in to the CD4+ T cell culture activated by different antigen doses, and 10%–20% of the CD8+ T cells adding into CD4+ T cell culture was chosen to reveal optimal inhibition effect of the CD8+ T cells. We also established that in this system, the MHC class II–restricted antigen peptides tested had minimal effect on the CD8+ T cells added. During the last 18 hours of the 5- to 6-day culture, [3H]thymidine was added (1 μCi/well), and incorporation of labeling was measured by liquid scintillation counting. Cell proliferation, in counts per minute, was plotted against antigen concentration, and ED50 value was derived by calculating the intercept of antigen concentration leading to half maximum proliferation as described in our previous studies (6–8). We also designed a new parameter to evaluate the function of self/nonself discrimination of the T cells, the SND index: antigen doses that elicit the highest T cell proliferation between immune response to self-antigens versus to foreign antigens in each individual, as described in detail in the text. Statistical analysis (2-tailed Student’s t test) of the SND indexes was used to evaluate the significant differences among different groups; differences were considered significant when P was less than 0.05.
The authors thank Yifan Liu for technical help, Ellen M. Greenberg for coordinating clinical studies, and Robin Goland at the NBDC, Columbia University, for support. The studies described in this manuscript have been supported by NIH grants R01 AI065609 to H. Jiang and U19 AI46132 to L. Chess and H. Jiang; and grants from the National Natural Science Foundation of China (NSF-30830093) and National Key Program (no. 973) for Basic Research of China (2009CB522409) to H. Jiang.
Address correspondence to: Hong Jiang, Columbia University, College of Physicians and Surgeons, Department of Medicine, 630 W 168th Street, PH8-406, New York, New York 10032, USA. Phone: 212.305.6979; Fax: 212.305.4943; E-mail: hj4@columbia.edu.
Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J Clin Invest. 2010;120(10):3641–3650. doi:10.1172/JCI43522.
See the related article at Comeback kids: CD8+ suppressor T cells are back in the game.